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Background: Metabolic syndrome (MetS) and insulin resistance (IR) are increasing in prevalence, are associated
with higher risk for coronary heart disease (CHD), and may potentially influence the responses to lipid-altering drug
therapy. This study evaluated the effects of MetS factors (abdominal obesity, depleted high-density lipoprotein
cholesterol [HDL-C], and elevated triglycerides, blood pressure, and fasting glucose) and IR on ezetimibe/simvastatin
and atorvastatin treatment efficacy in patients with MetS.
Methods: This post-hoc analysis of a multicenter, 6-week, double-blind, randomized, parallel group study of 1128
subjects with hypercholesterolemia, MetS, and moderately high/high CHD risk evaluated the effects of baseline
MetS factors/IR on percent change from baseline in lipids, apolipoproteins, and high-sensitivity C-reactive protein
(hs-CRP), after treatment with the usual starting doses of ezetimibe/simvastatin (10/20 mg) versus atorvastatin
(10 mg, 20 mg) and next higher doses (10/40 mg versus 40 mg).
Results: Ezetimibe/simvastatin and atorvastatin efficacy was generally consistent across MetS factor/IR subgroups.
Ezetimibe/simvastatin produced greater incremental percent reductions in LDL-C, non-HDL-C, apolipoprotein B,
total cholesterol, and lipoprotein ratios for all subgroups, and larger percent increases in HDL-C and apolipoprotein
AI for all but non-obese and HDL-C ≥40 mg/dL subgroups than atorvastatin at the doses compared. Triglycerides,
very-LDL-C, and hs-CRP results were more variable but similar between treatment groups.
Conclusion: The magnitude of lipid-altering effects produced by each treatment regimen was generally similar
across all MetS and IR subgroups. Ezetimibe/simvastatin produced greater percent reductions in most lipid fractions
than atorvastatin at the dose comparisons studied, and all treatments were generally well tolerated. (Registered at
clinicaltrials.gov: NCT00409773)* Correspondence: jrosen@crsouthflorida.com
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Metabolic syndrome is a cluster of factors that substan-
tially increase the risk for atherosclerotic cardiovascular
disease and diabetes [1, 2]. The estimated prevalence of
metabolic syndrome found in most industrialized coun-
tries is 20-30 % [3–5]. For the United States, the National
Health and Nutrition Examination Survey (NHANES) age
adjusted data from 2003 to 2006 estimated that 34 % of
Americans had metabolic syndrome, representing a 10 %
increase over the previous 10–15 years [6]. The increased
prevalence of metabolic syndrome is a worldwide public
health issue, driven primarily by higher rates of obesity
and an aging population [3, 4]. These observations high-
light the urgent need for effective strategies to treat the
underlying causes of metabolic syndrome, including
weight loss, increased physical activity, and management
of factors responsible for elevated cardiometabolic risk.
Recently defined criteria used to diagnose metabolic syn-
drome include abdominal obesity (waist circumference),
dyslipidemia (reduced levels of high-density lipoprotein
cholesterol [HDL-C] and high triglycerides), elevated blood
pressure, and elevated fasting glucose [7]. Several national
and international organizations have provided guidance for
the management of metabolic syndrome and associated
cardiovascular risk and for those patients with dyslipidemia
[1, 8–12] Many international guidelines recommend spe-
cific treatment targets for low-density lipoprotein choles-
terol (LDL-C), non-HDL-C, and apolipoprotein (apo) B
levels based on cardiovascular risk; however the 2013
American College of Cardiology (ACC)/American Heart
Association (AHA) guidelines focus on the identification of
patient groups most likely to benefit from treatment with
high-intensity statins that will result in LDL-C lowering by
≥50 % or by 30 to <50 %, respectively [12]. Obesity and in-
sulin resistance modulate the normal pattern of lipid me-
tabolism which promotes the development of atherogenic
dyslipidemia, including higher levels of triglyceride-rich
very-low density lipoprotein (VLDL), greater numbers of
apo B-containing small-dense LDL particles, and in-
creased clearance of circulating HDL [13]. These meta-
bolic changes may potentially influence the efficacy of
lipid-altering drugs, and it is therefore important to deter-
mine the effects of metabolic syndrome factors and insulin
resistance on treatment.
The Vytorin in Metabolic Syndrome (VYMET) study
was conducted in patients with metabolic syndrome,
hypercholesterolemia, and either moderately high or
high coronary heart disease (CHD) risk. Primary analysis
of this study showed that after 6 weeks of treatment,
ezetimibe/simvastatin produced significantly greater im-
provements in LDL-C and other key lipid parameters
than atorvastatin at the doses compared [14]. The ob-
jective of this current post hoc analysis was to evaluate




This post hoc analysis evaluated data from the previously
reported multicenter, randomized, double-blind, 5-arm,
parallel-group VYMET study (NCT00409773; protocol
number 107) that was designed to assess the lipid-
altering efficacy of ezetimibe/simvastatin and atorva-
statin in subjects with metabolic syndrome and elevated
cardiovascular risk [14]. The protocol was approved by
the institutional review board or ethics committee of
each participating study site, and all patients provided
written informed consent.
Subjects and therapy
Details of the study have been described previously [14].
In short, participants eligible for inclusion in this study
were men and women from 18 to 79 years old with a diag-
nosis of metabolic syndrome, hypercholesterolemia, and
at moderately high or high risk of CHD. Metabolic syn-
drome was defined according to the 2005 AHA/National
Heart Lung and Blood Institute criteria as having three or
more of the following five characteristics; abdominal obes-
ity (waist circumference of ≥102 cm [≥40 in] for men or
≥88 cm [≥35 in] for women); triglycerides ≥150 mg/dl;
HDL-C <40 mg/dl in men or <50 mg/dl in women; blood
pressure ≥130 mm Hg systolic blood pressure or ≥85 mm
Hg diastolic blood pressure or on antihypertensive drug
treatment in a subject with a history of hypertension; and
fasting glucose ≥100 mg/dl or on drug treatment for ele-
vated glucose [1]. High-risk subjects with CHD or other
forms of atherosclerotic vascular disease (AVD, including
peripheral arterial disease, atherosclerotic aortic disease,
and carotid artery disease [15]) were required to have
baseline LDL-C levels ≥70 mg/dl. High-risk subjects with-
out AVD (diabetes or multiple risk factors and a 10-year
risk level for CHD >20 %) and moderately high-risk
subjects (10-year risk level for CHD of 10 to 20 %) were
required to have baseline LDL-C levels ≥100 mg/dl. Eli-
gible subjects who had not received treatment with
lipid-lowering agents including over-the-counter diet-
ary supplements of fish oils containing >1000 mg/day
of EPA + DHA, rice yeast extract, Cholestin, bile-acid
sequestrants, HMG-CoA reductase inhibitors, ezeti-
mibe, ezetimibe/simvastatin; and niacin (>200 mg/day)
within 6 weeks (8 weeks for fibrates) prior to the first
study visit and were at high risk for CHD, or those re-
ceiving lipid-lowering therapy who were at moderately
high risk for CHD, were randomized to treatment with
the recommended starting doses of ezetimibe/simva-
statin (10/20 mg) versus atorvastatin (10 and 20 mg) or
Rosen et al. Lipids in Health and Disease  (2015) 14:103 Page 3 of 12next higher doses of ezetimibe/simvastatin (10/40 mg)
versus atorvastatin (40 mg) for 6 weeks.
Statistical analysis
Consistent with the main study, this post hoc subgroup
analysis included all randomized subjects with a baseline
and at least one post-baseline evaluation. Subgroups in-
cluded the presence or absence of individual metabolic
syndrome factors; abdominal obesity (yes, no), triglycer-
ides ≥ 150 mg/dl (yes, no), HDL-C < 40 mg/dl for males
or <50 mg/dl for females (yes, no), systolic blood pres-
sure ≥130 mmHg or diastolic blood pressure ≥85 mmHg
(yes, no), fasting glucose ≥100 mg/dl (yes, no); and insu-
lin resistance tertiles (estimated using the Homeostasis
Model Assessment of Insulin Resistance (HOMA-IR)
score [16]: fasting serum insulin (mU/l) X fasting glu-
cose (mmol/l)/22.5 [<2.72, 2.72-4.81, >4.81]). Treatment
efficacy of ezetimibe/simvastatin 10/20 mg versus ator-
vastatin 10 mg and 20 mg, and ezetimibe/simvastatin
10/40 mg compared with atorvastatin 40 mg was evalu-
ated within each subgroup using an analysis of variance
(ANOVA) model with terms for subgroup, baseline risk
stratum, treatment, and treatment by subgroup inter-
action. Efficacy endpoints included percent change from
baseline in LDL-C, HDL-C, non-HDL-C, total choles-
terol, VLDL-C, triglycerides, apo B, apo AI, lipid/lipo-
protein ratios (total cholesterol:HDL-C, LDL-C:HDL-C,
apo B:apo AI, non-HDL-C:HDL-C) and high-sensitivity
C-reactive protein (hs-CRP) after 6 weeks of therapy.
Least squares mean was determined for LDL-C, HDL-
C, non-HDL-C, total cholesterol, VLDL-C, apo B, apo
AI, and lipid/lipoprotein ratios, and estimates of
between-treatment differences (ezetimibe/simvastatin
minus atorvastatin) and corresponding 95 % confidence
intervals (CIs) were determined using the ANOVA
model. Median values were determined for triglycerides
and hs-CRP, and estimates of between-treatment group
differences and corresponding 95 % CIs were based on
Hodges-Lehmann estimates of shift. Given the large num-
ber of comparisons and the post-hoc nature of the ana-
lyses, inferential statistics were not conducted in order to
avoid issues of multiplicity.
Safety and tolerability were assessed within metabolic
syndrome factor and insulin resistance subgroups. Clinical
adverse experiences (AEs) were evaluated for all patients
who were randomized and received at least one dose of
study medication, and included any clinical AE, drug-
related AE, serious AE, discontinuations due to an AE,
and deaths. Laboratory AEs were evaluated for all subjects
who had at least one post-baseline assessment, and in-
cluded consecutive ≥ 3X the upper limit of normal
(ULN) elevations in aspartate aminotransferase and/or
alanine aminotransferase, ≥ 10X the ULN increases in
creatine kinase with or without muscle symptoms, anda summary by system organ class and specific adverse
experience term.
Results
As reported previously, of the 1,143 subjects randomized
to treatment, 658 subjects receiving atorvastatin mono-
therapy and 438 receiving ezetimibe/simvastatin com-
pleted the trial [14]. Baseline demographics within each
metabolic syndrome factor and insulin resistance sub-
group were generally similar to those found for the over-
all study population, [14] a predominantly white (75 %)
and male (56 %) cohort with a mean age of 59 years
(Table 1). Over half of the population was obese (body
mass index ≥30 kg/m2), approximately 50-60 % was dia-
betic, and one third was classified as high CHD risk sub-
jects with AVD. For each subgroup evaluation, baseline
characteristics and lipid values were generally well bal-
anced across the ezetimibe/simvastatin and atorvastatin
treatment groups. As expected, baseline values for some
parameters varied within a few subgroups due to the as-
sociation between the parameter being evaluated and the
subgroup category (i.e., the percentage of subjects with
diabetes was much higher for the subgroup with fasting
glucose levels ≥100 mg/dl [72-74 %] than for those with
levels <100 mg/dl [10-11 %]; baseline triglyceride values
were the highest in the subgroup of subjects with trigly-
ceride levels ≥150 mg/dl). Variation in baseline values
were noted for some categories (Black, Other) and sub-
groups (waist circumference < 40 in [<50 in for females],
systolic blood pressure <130 mmHG [diastolic blood
pressure <85 mmHg]) which was due in part to the
small number of subjects being evaluated.
Ezetimibe/simvastatin (10/20 mg, 10/40 mg) and atorva-
statin (10, 20, 40 mg) therapy produced relatively consist-
ent lipid-altering effects across all metabolic syndrome
factor and insulin resistant subgroups, which were similar
in magnitude to those previously reported for the overall
study population (Fig. 1) [14]. All treatments produced
significant reductions from baseline in LDL-C, non-HDL-
C, total cholesterol, apo B, triglycerides, and lipid/lipopro-
tein ratios (total cholesterol:HDL-C, LDL-C:HDL-C, apo
B:apo AI, non-HDL-C:HDL-C, data not shown) for all
subgroups. VLDL-C (data not shown) and hs-CRP
changes from baseline were also significant for most sub-
group evaluations and consistent with the changes
observed for the full cohort. Increases in HDL-C were
observed for all subgroups except two (subjects receiving
atorvastatin 10 mg and 20 mg with systolic blood pressure
<130 mm Hg [diastolic <85 mm Hg], n = 11 and 21, re-
spectively) and most changes were nominally significant.
Elevations in apo AI were smaller in magnitude than
HDL-C, and most were not significantly different from
baseline (data not shown). When comparing ezetimibe/
simvastatin 10/20 mg with atorvastatin 10 mg or 20 mg,
Table 1 Baseline demographics, lipids, lipoproteins, and hs-CRP
Abdominal Obesitya males (females) TG HDL-C males (females) SB (DBP)




























Mean Age (SD) 59.2 (9.0) 62.4 (7.5) 58.7 (9.7) 59.3 (9.6) 60.2 (9.4) 60.3 (9.2) 58.1 (9.7) 59.3 (9.6) 60.5 (9.5) 60.7 (9.6) 57.5 (9.6) 58.8 (9.3) 53.5 (9.5)
Female, n(%) 24 (25.5) 9 (16.1) 281 (48.0) 180 (45.1) 106 (50.0) 68 (46.6) 201 (42.4) 123 (39.5) 107 (37.3) 66 (33.8) 200 (50.1) 125 (47.7) 31 (55.4)
White, n(%) 68 (72.3) 37 (66.1) 443 (75.6) 301 (75.4) 157 (74.1) 106 (72.6) 359 (75.7) 234 (75.2) 231 (80.5) 162 (83.1) 285 (71.4) 178 (67.9) 47 (83.9)
Black, n(%) 4 (4.3) 4 (7.1) 41 (7.0) 26 (6.5) 21 (9.9) 17 (11.6) 24 (5.1) 13 (4.2) 13 (4.5) 11 (5.6) 32 (8.0) 19 (7.3) 2 (3.6)
Other, n(%) 22 (23.4) 15 (26.8) 102 (17.4) 72 (18.0) 34 (16.0) 23 (15.8) 91 (19.2) 64 (20.6) 43 (15.0) 22 (11.3) 82 (20.6) 65 (24.8) 7 (12.5)
CHD n(%) 25 (26.6) 17 (30.4) 104 (17.7) 76 (19.0) 46 (21.7) 30 (20.5) 84 (17.7) 63 (20.3) 47 (16.4) 33 (16.9) 83 (20.8) 60 (22.9) 7 (12.5)
With AVD, n(%) 32 (34.0) 21 (37.5) 162 (27.6) 117 (29.3) 65 (30.7) 44 (30.1) 131 (27.6) 94 (30.2) 80 (27.9) 53 (27.2) 116 (29.1) 85 (32.4) 8 (14.3)
BMI≥ 30 kg/m2, n(%) 16 (17.2) 7 (12.5) 387 (66.5) 267 (66.9) 133 (63.0) 89 (61.0) 276 (58.7) 186 (59.8) 164 (57.5) 112 (57.4) 245 (61.9) 163 (62.2) 31 (55.4)
Diabetes, n(%) 39 (41.5) 13 (23.2) 339 (57.8) 221 (55.4) 145 (68.4) 96 (65.8) 236 (49.8) 140 (45.0) 159 (55.4) 116 (59.5) 222 (55.6) 120 (45.8) 42 (75.0)
Metabolic Syndrome, n(%) 70 (74.5) 41 (73.2) 566 (96.6) 387 (97.0) 180 (85.3) 128 (88.3) 461 (97.3) 301 (96.8) 248 (86.7) 171 (87.7) 393 (98.5) 258 (98.9) 48 (85.7)
TG≥ 150 mg/dL, n(%) 73 (77.7) 41 (73.2) 397 (67.7) 269 (67.4) 0 0 474 (100) 311 (100) 176 (61.3) 116 (59.5) 298 (74.7) 195 (74.4) 45 (80.4)
Low HDL-C, n(%) 58 (61.7) 36 (64.3) 337 (57.5) 224 (56.1) 101 (47.6) 67 (45.9) 298 (62.9) 195 (62.7) 0 0 399 (100) 262 (100) 47 (83.9)
Elevated BP, n(%) 85 (90.4) 53 (94.6) 539 (92.0) 365 (91.5) 201 (94.8) 141 (96.6) 429 (90.5) 279 (89.7) 278 (96.9) 189 (96.9) 352 (88.2) 231 (88.2) 0
FG≥ 100 mg/dL, n(%) 55 (58.5) 30 (53.6) 431 (73.5) 275 (68.9) 176 (83.0) 117 (80.1) 314 (66.2) 189 (60.8) 213 (74.2) 145 (74.4) 277 (69.4) 161 (61.5) 43 (76.8)
LDL-C 138.2 (34.5) 139.1 (33.1) 140.6 (35.7) 135.1 (30) 131.1 (28.9) 133 (29.7) 144.4 (37.5) 136.6 (30.8) 145.7 (34.7) 138.5 (31.2) 136.4 (35.7) 133.2 (29.7) 140.6 (39.7)
HDL-C 41.5 (9.7) 42.5 (12.4) 43.3 (10.3) 43.2 (10.8) 46.3 (11.5) 46.8 (12.8) 41.6 (9.3) 41.3 (9.6) 50.3 (10.1) 50.7 (11.2) 37.8 (6.5) 37.6 (6.9) 41.4 (8.1)
non-HDL-C 177.4 (40.9) 179.8 (35.4) 181.1 (40.5) 174.6 (35.8) 156.9 (30.3) 157.9 (31.3) 191.3 (40.1) 183.2 (35) 181.7 (40.7) 173.5 (37.4) 179.9 (40.5) 176.1 (34.6) 182.7 (43.4)
TGb 171.5 (97.7) 188 (118.6) 186 (99.1) 177 (101.4) 123 (41.4) 121 (42.8) 215 (93.7) 215 (97.7) 162 (85.1) 157.5 (81.9) 200 (106) 199.8 (114.9) 194 (86.7)
Total C 218.9 (42.9) 222.3 (39.1) 224.3 (41.1) 218.1 (36.4) 203.2 (33.4) 204.8 (32.5) 232.8 (41.5) 224.9 (37) 232 (40.1) 224.2 (37.7) 217.6 (41.4) 214.2 (35.7) 223.3 (44.1)
Apo B 134.3 (29.2) 137.6 (25.2) 137.3 (30.1) 133.4 (26.5) 121.6 (23.2) 122.7 (22.1) 143.8 (30.3) 138.9 (26.9) 136.5 (29.5) 131.5 (25.9) 137.2 (30.5) 135.2 (26.8) 141.5 (33.2)
Apo AI 140.4 (24.6) 141.5 (27.7) 144.8 (24.3) 144.8 (25.5) 145 (26.3) 146.3 (27.9) 143.7 (23.6) 143.4 (24.6) 157.7 (24.8) 160.7 (26.2) 134.3 (18.8) 132.7 (17.9) 141 (20.1)















Table 1 Baseline demographics, lipids, lipoproteins, and hs-CRP (Continued)
SB (DBP) FG HOMA-IR
<130 mmHg
(<85 mgHg)



























Mean Age (SD) 51.6 (11.2) 59.2 (9.5) 60.3 (8.9) 59 (10.2) 58.8 (8.9) 58.7 (9.4) 60 (9.7) 60 (10.3) 60. 9 (8.6) 58.5 (8.7) 59.9 (9.9) 57. 6 (9.7) 58.2 (9.5)
Female, n(%) 13 (35.1) 276 (43.8) 178 (42.4) 78 (39.8) 51 (33.8) 229 (46.7) 140 (45.8) 102 (44.0) 57 (39.3) 100 (44.4) 67 (44.1) 100 (45.9) 66 (42.6)
White, n(%) 26 (70.3) 469 (74.4) 314 (74.8) 129 (65.8) 99 (65.6) 387 (79.0) 241 (78.8) 166 (71.6) 99 (68.3) 164 (72.9) 113 (74.3) 176 (80.7) 124 (80.0)
Black, n(%) 1 (2.7) 43 (6.8) 29 (6.9) 17 (8.7) 9 (6.0) 28 (5.7) 21 (6.9) 11 (4.7) 9 (6.2) 21 (9.3) 10 (6.6) 13 (6.0) 11 (7.1)
Other, n(%) 10 (27.0) 118 (18.7) 77 (18.3) 50 (25.5) 43 (28.5) 75 (15.3) 44 (14.4) 55 (23.7) 37 (25.5) 40 (17.8) 29 (19.1) 29 (13.3) 20 (12.9)
CHD n(%) 5 (13.5) 123 (19.5) 88 (21.0) 52 (26.5) 32 (21.2) 78 (15.9) 61 (19.9) 45 (19.4) 34 (23.4) 44 (19.6) 30 (19.7) 37 (17.0) 28 (18.1)
With AVD, n(%) 8 (21.6) 188 (29.8) 130 (31.0) 75 (38.3) 48 (31.8) 121 (24.7) 90 (29.4) 66 (28.4) 49 (33.8) 68 (30.2) 44 (28.9) 58 (26.6) 43 (27.7)
BMI≥ 30 kg/m2, n(%) 23 (62.2) 378 (60.5) 252 (60.0) 96 (49.0) 80 (53.0) 313 (64.5) 195 (63.7) 91 (39.6) 60 (41.4) 141 (62.7) 102 (67.1) 170 (78.3) 110 (71.0)
Diabetes, n(%) 19 (51.4) 339 (53.8) 217 (51.7) 19 (9.7) 16 (10.6) 362 (73.9) 220 (71.9) 89 (38.4) 52 (35.9) 128 (56.9) 80 (52.6) 156 (71.6) 103 (66.5)
Metabolic Syndrome, n(%) 34 (91.9) 593 (94.3) 395 (94.3) 168 (85.7) 130 (86.7) 473 (96.7) 299 (97.7) 203 (87.9) 124 (86.1) 214 (95.1) 148 (97.4) 213 (97.7) 152 (98.1)
TG≥ 150 mg/dL, n(%) 32 (86.5) 429 (68.1) 279 (66.4) 160 (81.6) 122 (80.8) 314 (64.1) 189 (61.8) 156 (67.2) 92 (63.4) 160 (71.1) 105 (69.1) 152 (69.7) 109 (70.3)
Low HDL-C, n(%) 31 (83.8) 352 (55.9) 231 (55.0) 122 (62.2) 101 (66.9) 277 (56.5) 161 (52.6) 122 (52.6) 85 (58.6) 128 (56.9) 88 (57.9) 143 (65.6) 87 (56.1)
Elevated BP, n(%) 0 630 (100) 420 (100) 183 (93.4) 142 (94.0) 447 (91.2) 278 (90.8) 212 (91.4) 134 (92.4) 205 (91.1) 139 (91.4) 204 (93.6) 142 (91.6)
FG≥ 100 mg/dL, n(%) 28 (75.7) 447 (71.0) 278 (66.2) 0 0 490 (100) 306 (100) 124 (53.4) 70 (48.3) 165 (73.3) 102 (67.1) 192 (88.1) 132 (85.2)
LDL-C 131.9 (24.1) 140.2 (35.2) 135.7 (30.9) 148.2 (35.3) 139.7 (29.4) 137.1 (35.2) 133.4 (30.8) 146.7 (35.7) 142 (32.6) 139 (36.2) 134.8 (29.9) 135.6 (34.2) 130 (28)
HDL-C 37.3 (8.1) 43.2 (10.4) 43.6 (11.1) 41.9 (10.7) 40.4 (10.2) 43.5 (10.1) 44.4 (11.2) 44.2 (11.1) 42.9 (10.6) 43 (9.3) 43.7 (11.2) 41.8 (10.1) 43 (11.3)
non-HDL-C 181.6 (35.6) 180.5 (40.3) 174.4 (35.8) 191.8 (40.8) 182.4 (34.5) 176.3 (39.7) 171.5 (35.9) 183 (40.6) 178.5 (38) 181.3 (41.7) 174.8 (33.6) 178.1 (40) 171.9 (36.1)
TGb 217 (141.4) 181.5 (100) 175 (104.2) 201 (105.1) 201 (94.9) 175.8 (99.1) 161.5 (101.4) 167.5 (91.2) 174 (90.2) 183 (109.8) 177.5 (122.3) 196.3 (99.1) 183.5 (109.3)
Total C 218.9 (35) 223.6 (41.2) 218.4 (37) 233.6 (43.3) 222.8 (36.1) 219.7 (40) 216.3 (37) 227 (41.3) 222.4 (41.2) 224.4 (41.9) 218.5 (33.2) 219.9 (41.6) 214.8 (36.1)
Apo B 138.5 (26.1) 136.5 (29.8) 133.3 (26.5) 144.1 (30.3) 139.8 (25.4) 134 (29.6) 130.7 (26.6) 138.2 (29.5) 138 (27.8) 137.1 (32.3) 132.7 (24.7) 135.5 (28.8) 130.3 (26.5)
Apo AI 136.8 (25.6) 144.4 (24.8) 145 (25.7) 142.1 (26.6) 138.4 (24.7) 144.9 (23.5) 147.2 (25.8) 143.6 (26.5) 142.3 (24.4) 144.7 (22.9) 146.3 (25.4) 143.9 (23.5) 144.5 (27.4)
hs-CRPb 4.2 (4) 3 (4.6) 2.9 (4.6) 2.9 (3.8) 2.5 (3.1) 3 (4.7) 3.5 (5.3) 2.3 (3.6) 2.3 (3.9) 3 (4) 3.1 (4) 4 (5.3) 3.5 (6)
Apo = apolipoprotein; All A = data for all atorvastatin doses (10/20/40 mg) combined; Apo = apolipoprotein; BMI = body mass index; BP = blood pressure; All E/S = data for all ezetimibe/simvastatin doses (10/20 mg, 10/40 mg)
combined; FG = fasting glucose; HDL-C = high density lipoprotein cholesterol; hsCRP = high-sensitivty C-reactive protein, LDL-C = low density lipoprotein cholesterol, n = number of patients in subgroup (numbers vary slightly
between parameters), TG = triglycerides; SD = standard devation ametabolic syndrome defined as ≥3 of the following 5 characteristics; abdominal obesity (waist circumference ≥40 inches (males) or ≥35 inches (females)),















Fig. 1 Percent change from baseline in lipid, lipoprotein, and hs-CRP by treatment and metabolic syndrome/IR subgroup. Error bars = standard
error. Arrows indicate percent change from baseline reported for the overall study population [13], with associated value given below the
measured parameter for each treatment group. A10/20/40 = atorvastatin 10/20/40 mg; Apo = apolipoprotein; BP = blood pressure [systolic
blood pressure (diastolic blood pressure)]; E10/S20(40) = ezetimibe 10 mg/simvastatin 20(40) mg; FG = fasting glucose; HDL-C = high density
lipoprotein cholesterol; IR = Homeostasis Model Assessment of Insulin Resistance tertiles; hs-CRP = high-sensitivity C-reactive protein,
LDL-C = low- density lipoprotein cholesterol; Ob = abdominal obesity (waist circumference ≥40 inches for males or ≥35 inches for
females); TG = triglycerides
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40 mg, treatment with ezetimibe/simvastatin produced
generally greater percent reductions from baseline in
LDL-C, non-HDL-C, Apo B, total cholesterol, and lipo-
protein ratios (data not shown) for all but four subgroup
comparisons, with between treatment differences rangingfrom 0.4 to 27.6 % (Table 2); atorvastatin 40 mg pro-
duced greater reductions than ezetimibe/simvastatin
10/40 mg for LDL-C by 2.0 %, LDL-C:HDL-C by 4.5 %
and apoB:apoA1 by 1.3 % for subjects with waist circum-
ferences <40/35 inches, and similar reductions in apoB
(0.1 %) for subjects with blood pressure <130/85 mm Hg.
Table 2 Percent differences within metabolic syndrome and insulin resistance subgroups in LDL-C, total cholesterol, HDL-C and triglycerides
Abdominal Obesitya TG HDL-C SBP (DBP) FG HOMA-IR
No Yes <150 mg/dL ≥150 mg/
dL




<100 mg/dL ≥100 mg/dL <2.72 2.72-4.81 >4.81
n = 20-36 n = 177-196 n = 62-77 n = 142-155 n = 82-99 n = 119-135 n = 11-21 n = 194-205 n = 52-75 n = 144-165 n = 57-81 n = 68-78 (n = 69-79
LDL-C, mg/dL
(95 % CI)














































































































































































































































TG, mg/dL (95 % CI)














































































A10/20/40 = atorvastatin 10/20/40 mg; E = ezetimibe 10 mg; FG = fasting glucose; HDL-C = high density lipoprotein cholesterol; HOMA-IR = Homeostasis Model Assessment of Insulin Resistance; LDL-C = low
density lipoprotein cholesterol, n = number of patients in subgroup (some numbers vary slightly
between parameters), S20/40 = simvastatin 20/40 mg; SBP (DBP) = systolic blood pressure (diastolic blood pressure); SD = standard deviation; TG = triglycerides
*Confidence intervals of difference parameters do not contain 0 aabdominal obesity = waist circumference ≥40 inches for males or ≥35 inches for females bbetween-treatment differences (E+S minus A) based on ANOVA model with
terms for subgroup (baseline abdominal obesity, TG, HDL-C, blood pressure, fasting glucose, and HOMA-IR, based on subgroup being analyzed), baseline stratum, treatment group, and the interaction of treatment group and















Table 3 Adverse experience summary of pooled treatment groups
Adverse
Experience
Obesity TG HDL-C SB/ DBP FG HOMA-IR
males/females males/females



































































































































































































































0 (0) 0 (0) 1
(0.2)




0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (0.2) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1
(0.5)















































































serious 0 (0) 0 (0) 2
(0.3)











0 (0) 0 (0) 1
(0.2)




0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (0.2) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1
(0.5)
0 (0) 0 (0) 0 (0)








































































































































































































































































































































































































































































































































































































Although a patient may have had two or more clinical adverse experiences the patient is counted only once in a category. The same patient may appear in different categories
E = Ezetimibe 10 mg; All Atorva = Atorvastatin(10,20,40 mg) pooled across all doses; E/All Simva = Ezetimibe/Simvastatin(10/20, 10/40 mg) pooled across all doses; n = Number of randomized and treated patients in each
treatment group
aDetermined by the investigator to be possibly, probably, or definitely related to the drug
bFor laboratory safety (ALT, AST, CK), patients must have taken at least one dose of study medication and have at least one postbaseline measurement within 14 days of the last dose of study therapy to be included in
the analysis
% =m/n x 100 = (number of patients within the Tier 1 adverse event category / number of treated patients [with one or more laboratory tests postbaseline, if parameter is a laboratory parameter]) × 100
cThis category includes those patients with (a) two consecutive measurements ≥3xULN, (b) a single, last measurement ≥3xULN, or (c) a measurement ≥3xULN followed by a measurement <3xULN that was taken more than
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lipid-lowering effects of ezetimibe/simvastatin were greater
than atorvastatin at the doses compared for most sub-
groups (Table 2), which is consistent with the significantly
greater differences previously reported for the entire co-
hort (Fig. 1) [14]. When compared with atorvastatin, ezeti-
mibe/simvastatin produced numerically larger percent
increases in HDL-C and apo AI for all but three subgroups
(non-obese, HDL-C ≥40 mg/dl, and HOMA-IR 2.72-4.81
(Table 2). The percent changes from baseline in VLDL-C
(not shown), triglycerides, and hs-CRP were similar for the
majority of ezetimibe/simvastatin and atorvastatin com-
parisons and were consistent with the similar treatment ef-
fects seen for the overall study.
All doses of ezetimibe/simvastatin and atorvastatin
were generally safe and well tolerated, with an incidence
of one or more adverse experiences (11.3 to 23.2 %),
drug-related adverse experiences (1.4 to 5.7 %), and ser-
ious adverse experiences (0 to 1.8 %) that was generally
similar across all subgroups (Table 3) and consistent
with the primary study results [14]. The statistical sig-
nificance of differences between subgroups and between
treatments within each subgroup was not evaluated due
to the post hoc nature of these analyses.
Discussion
This post hoc study of subjects with hypercholesterol-
emia, metabolic syndrome, and moderately high or high
CHD risk was designed to evaluate the effect of individ-
ual metabolic syndrome factors and insulin resistance on
the lipid-lowering efficacy of ezetimibe/simvastatin (10/
20 mg, 10/40 mg) and atorvastatin (10, 20, 40 mg).
Results showed a consistent treatment effect for both
ezetimibe/simvastatin and atorvastatin when comparing
subjects with to those without the individual metabolic
syndrome factors of abdominal obesity (based on waist
circumference), elevated triglycerides, low HDL-C, high
blood pressure, and fasting glucose ≥100 mg/dl; or
within low, middle, or high tertile subgroups of insulin
resistance as measured by HOMA-IR. The magnitude of
lipid-altering effects produced by each treatment regi-
men was generally similar across all subgroups, suggesting
that ezetimibe/simvastatin and atorvastatin treatment ef-
fects are not substantively influenced by these factors. Eze-
timibe/simvastatin produced greater percent reductions in
LDL-C, non-HDL-C, apo B, total cholesterol, and lipid/
lipoprotein ratios than atorvastatin for most subgroups
and dose comparisons. These effects were similar to the
results reported for the overall study cohort [14] and con-
sistent with three other studies designed to evaluate ezeti-
mibe/simvastatin and atorvastatin efficacy in subjects at
moderately high or high CHD risk with hypercholesterol-
emia (VYVA) [17], with diabetes mellitus and hypercholes-
terolemia (VYTAL) [18], or with advanced age (≥65 years)and hypercholesterolemia (VYTELD) [19]. In addition, a
post hoc multivariate analysis demonstrated that ezetimibe/
simvastatin treatment was consistently more effective than
atorvastatin treatment in at-risk patients with the MetS in
patients ≥65 years, in those with abdominal obesity, and
with lower baseline hs-CRP at the specified dose compari-
sons (VYMET) [20].
The altered regulation of lipid metabolism found in
patients with metabolic syndrome, including low HDL-
C, high triglycerides, and elevated concentrations of
small-dense LDL (sdLDL) particles, seems to play a
major role in elevating cardiovascular disease risk [13].
In patients with metabolic syndrome, high triglyceride
content in the liver is associated with the increased hep-
atic secretion of triglyceride-rich VLDL. Cholesteryl ester
transfer protein (CETP) mediates the exchange of cho-
lesteryl ester for triglyceride between triglyceride-rich li-
poproteins and HDL, resulting in HDL with increased
susceptibility to hepatic lipase, generation of smaller
HDL particles, and accelerated HDL catabolism. A simi-
lar CETP-mediated process is responsible for the forma-
tion of sdLDL; however, these particles have a slower
catabolic rate and increased atherogenicity [21]. Atorva-
statin has been shown to produce a dose-dependent re-
duction in sdLDL with a concomitant shift from the
more atherogenic small-dense to larger, less dense LDL
particles for subjects with hypertriglyceridemia [22] and
other forms of dyslipidemia [23]. Ezetimibe alone or in
combination with statins has also been shown to reduce
levels of sdLDL [24–26]. While lipid-lowering therapy
has a demonstrated effect on lowering sdLDL, effects of
individual metabolic syndrome factors or insulin resist-
ance on sdLDL kinetics during treatment are unknown
and require further investigation.
As seen for the overall study, all treatments were gen-
erally well tolerated and clinical adverse experiences
were similar across all metabolic syndrome factor and
insulin resistance subgroups. Because the subgroup sizes
were relatively small and the event rates were low over-
all, it is difficult to generalize these results for subgroups
of patients with individual components of the metabolic
syndrome or insulin resistance.
As a post hoc analysis, results from this study have sev-
eral limitations and should be interpreted with appropriate
caution. Since many of the subgroups were limited in size
when compared with the entire cohort and multiple com-
parisons were made, results may not truly be representative
of a given subpopulation. This study was also not designed
to have adequate power to determine the statistical signifi-
cance for between-treatment differences in subgroups.
These findings, however, are consistent with several prior
studies showing the greater lipid-lowering efficacy of ezeti-
mibe/simvastatin therapy versus statin monotherapy in pa-
tients with diabetes or metabolic syndrome [27–30]. The
Rosen et al. Lipids in Health and Disease  (2015) 14:103 Page 11 of 12short duration of this study precludes evaluation of long-
term treatment efficacy or safety.
In summary, results from this study suggest that ezeti-
mibe/simvastatin and atorvastatin efficacy is generally
well maintained across metabolic syndrome factor and
insulin resistance subgroups. Ezetimibe/simvastatin pro-
vided greater lipid-altering benefits for most key param-
eters than atorvastatin at the doses compared, which
may be of interest to clinicians when evaluating treat-
ment options for patients with metabolic syndrome and
moderately high to high CHD risk. Additional studies
will be needed to determine the final clinical significance
of these results.
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